New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
08:57 EDTTRGT, ARQLTargacept names Stephen A. Hill, M.D., president and CEO
Dr. Hill is expected to start with Targacept (TRGT) on December 1 and will also join Targaceptís Board of Directors. Dr. Hill brings over 20 years of industry experience to the role, having served previously as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and ArQule (ARQL). Upon Dr. Hill joining Targacept, the previously formed Office of the Chairman will be dissolved.
News For TRGT;ARQL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 14, 2015
09:22 EDTARQLLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:41 EDTTRGTTargacept says Catalyst CEO Nassim Usman to become CEO of combined company
Catalystís CEO Nassim Usman, Ph.D., will become the President and CEO of the combined company and the other Catalyst executive officers, Ed Madison, Ph.D., CSO and Fletcher Payne, CFO will assume their respective positions in the combined company. The seven-member board of directors of the combined company will be comprised of current Catalyst directors Harold E. Selick, Ph.D., Jeff Himawan, Ph.D., and Augustine Lawlor, as well as Dr. Usman, and current Targacept directors John P. Richard, Errol B. DeSouza, Ph.D. and Dr. Stephen A. Hill. Dr. Selick will serve as the new chairman of the board.
08:39 EDTTRGTTargacept, Catalyst Biosciences amend definitive merger agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use